Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 10/20 | 0.64 |
| ▸ | CA12 | O43570 | 8/20 | 0.64 |
| ▸ | CA7 | P43166 | 8/20 | 0.64 |
| ▸ | CA9 | Q16790 | 8/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25249160 | 1.00 | CA2 (1.00) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL16369614 | 1.00 | CA2 (1.00) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL25794676 | 0.88 | CA2 (0.78) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL5537767 | 0.87 | CA2 (0.75) | CA2TDP1L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL6787910 | 0.87 | CA2 (0.75) | CA2TDP1L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL3719685 | 0.86 | CA2 (0.76) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL25796761 | 0.84 | CA2 (0.73) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL25793176 | 0.84 | CA2 (0.73) | CA2TDP1L3MBTL1CA1CA12 | |
| SCHEMBL28069383 | 0.84 | CA2 (0.73) | CA2TDP1L3MBTL1CA1ALDH1A1 | |
| SCHEMBL4739555 | 0.82 | CA2 (0.70) | CA2TDP1L3MBTL1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019172-B1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10273263-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9745338-B2 | Pro-drug forming compounds | EVESTRA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-105636592-A | Pro-drug forming compounds | EVESTRA INC | 2016-06-01 | — | — | CN | disclosed |
| EP-3019172-A1 | PRO-DRUG FORMING COMPOUNDS | Evestra, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006691-A1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273263-B2 | Pro-drug forming compounds | SUCNR1, FURIN, OGFR | CA2 1019/4885TDP1 4318/4885L3MBTL1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.